06:56 AM EST, 12/20/2024 (MT Newswires) -- GSK (GSK) said Friday that the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first-line advanced ovarian cancer met its primary endpoint.

The trial demonstrated a statistically significant effect on progression-free survival versus the active comparator arm.

However, the company said that the key secondary endpoint of overall survival did not meet statistical significance and further analyses are ongoing.